Stock Scorecard
Stock Summary for INmune Bio Inc (INMB) - $2.09 as of 8/29/2025 3:31:19 PM EST
Total Score
7 out of 30
Safety Score
23 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for INMB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for INMB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for INMB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for INMB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for INMB (23 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for INMB
Financial Details for INMB
Company Overview |
|
|---|---|
| Ticker | INMB |
| Company Name | INmune Bio Inc |
| Country | USA |
| Description | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/29/2025 |
Stock Price History |
|
| Last Day Price | 2.09 |
| Price 4 Years Ago | 10.20 |
| Last Day Price Updated | 8/29/2025 3:31:19 PM EST |
| Last Day Volume | 520,605 |
| Average Daily Volume | 2,260,043 |
| 52-Week High | 10.50 |
| 52-Week Low | 1.89 |
| Last Price to 52 Week Low | 10.58% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 36.18 |
| Sector PE | 60.89 |
| 5-Year Average PE | -4.32 |
| Free Cash Flow Ratio | 1.66 |
| Industry Free Cash Flow Ratio | 20.54 |
| Sector Free Cash Flow Ratio | 30.76 |
| Current Ratio Most Recent Quarter | 4.20 |
| Total Cash Per Share | 1.26 |
| Book Value Per Share Most Recent Quarter | 1.09 |
| Price to Book Ratio | 1.88 |
| Industry Price to Book Ratio | 7.19 |
| Sector Price to Book Ratio | 26.74 |
| Price to Sales Ratio Twelve Trailing Months | 1,111.27 |
| Industry Price to Sales Ratio Twelve Trailing Months | 52.00 |
| Sector Price to Sales Ratio Twelve Trailing Months | 13.32 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 26,585,300 |
| Market Capitalization | 55,563,277 |
| Institutional Ownership | 21.18% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -40.24% |
| Reported EPS 12 Trailing Months | -2.49 |
| Reported EPS Past Year | -0.77 |
| Reported EPS Prior Year | -2.11 |
| Net Income Twelve Trailing Months | -55,508,000 |
| Net Income Past Year | -42,082,000 |
| Net Income Prior Year | -30,008,000 |
| Quarterly Revenue Growth YOY | 257.10% |
| 5-Year Revenue Growth | -82.17% |
| Operating Margin Twelve Trailing Months | -79,430.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 33,374,000 |
| Total Cash Past Year | 20,922,000 |
| Total Cash Prior Year | 35,848,000 |
| Net Cash Position Most Recent Quarter | 30,880,000 |
| Net Cash Position Past Year | 6,001,000 |
| Long Term Debt Past Year | 14,921,000 |
| Long Term Debt Prior Year | 15,000,000 |
| Total Debt Most Recent Quarter | 2,494,000 |
| Equity to Debt Ratio Past Year | 0.68 |
| Equity to Debt Ratio Most Recent Quarter | 0.92 |
| Total Stockholder Equity Past Year | 32,097,000 |
| Total Stockholder Equity Prior Year | 38,139,000 |
| Total Stockholder Equity Most Recent Quarter | 28,867,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -32,903,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.24 |
| Free Cash Flow Past Year | -33,361,000 |
| Free Cash Flow Prior Year | -11,980,000 |
Options |
|
| Put/Call Ratio | 0.36 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.27 |
| MACD Signal | -0.30 |
| 20-Day Bollinger Lower Band | 0.21 |
| 20-Day Bollinger Middle Band | 5.08 |
| 20-Day Bollinger Upper Band | 9.95 |
| Beta | 0.98 |
| RSI | 33.91 |
| 50-Day SMA | 5.95 |
| 150-Day SMA | 7.85 |
| 200-Day SMA | 8.19 |
System |
|
| Modified | 8/30/2025 2:21:18 AM EST |